Free Fastin Weight Loss Pills Offered By Fastin.Org
Posted on: Monday, 14 April 2008, 09:00 CDT
WEST NEW YORK, N.J., April 14 /PRNewswire/ -- Fastin, from Hi-Tech Pharmaceuticals, is by far the hottest-selling nutriceutical weight loss supplement on the market today. The folks at Fastin.org are so confident in the results achieved from a recent customer satisfaction survey that they are now offering a free trial on their web site http://www.fastin.org/.
The rights to Fastin were previously owned by Smith Kline Beecham Pharmaceuticals, and most recently acquired Hi-Tech Pharmaceuticals. Smith Kline Beecham developed phentermine HCL under the brand name Fastin up until 1998.
Fastin, from Hi-Tech, is a pharmaceutical-grade dietary supplement indicated for weight loss in extremely overweight individuals. Fastin has both immediate and delayed release profiles for appetite suppression, energy, and weight loss. Fastin's patent-pending formula contains B-methyl-phenethylamine, 37.5mg, and was developed with the help of Mark Wright, M.D., a bariatric physician.
Fastin is available only from a select group of retailers, but Fastin.org is the only site offering a free trial of the product. Frank Huerta, spokesperson for Fastin.org sales and marketing, released a statement saying, "We are pleased to offer Fastin to consumers on this trial basis and we're supremely confident that customers will continue to order the product because of the effectiveness. We've never offered something for free, but the folks at Hi-Tech have made a product that actually does what it's supposed to and we're excited to be working with them on this offer."
For additional information about the free Fastin promotion, call 1-877-807-2007 or visit http://www.fastin.org/
Press Contact: Frank Huerta 201-927-3872
This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com/.
Fastin.org
CONTACT: Frank Huerta of Fastin.org, +1-201-927-3872
Web site: http://www.fastin.org/
Source: PRNewswire
Related Articles
- Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States
- Loss of Production Even More Dangerous in Times of Low Oil Prices
- TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients With Erosive Esophagitis
- China Biopharma Reaches Agreement With a Regional Pharma to Launch New Pharmaceutical Products
- Examine the Chinese Markets for Weight Loss Diet Products
- TAP Pharmaceutical Products Inc. Files New Drug Application for TAK-390MR in Patients With Acid-Related Disorders
- Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
- Timothy R. Wright Appointed President of Tyco Healthcare's Pharmaceutical Products and Imaging Solutions Units
- Macugen(R) (Pegaptanib Sodium Injection) Named Innovative Pharmaceutical Product Of The Year At The 2005 Pharmaceutical Achievement Awards
 |
 |
User Comments (0)
RSS Feeds